Abstract 543P
Background
Interstitial pneumonia (IP) is the common and poor prognostic comorbidities in patients with non-small cell lung cancer (NSCLC) and is a known risk factor for immune checkpoint inhibitor (ICI)-induced pneumonitis. The aim of this study is to assess the incidence, severity and risk factors for pneumonitis induced by immune checkpoint inhibitor (ICI) monotherapy in NSCLC patients with idiopathic IP.
Methods
This is a multicenter, retrospective study in patients with (1) advanced or recurrent NSCLC, (2) comorbid idiopathic IP, and (3) receiving ICI monotherapy as second-line or later therapy. All CTs at baseline and at the onset of pneumonitis were centrally adjudicated by a board-certified radiologist. We performed logistic regression analysis to identify risk factors for pneumonitis using clinical characteristics, laboratory data and radiological findings as variables.
Results
Sixty-five patients were analyzed, with a median age of 71 years, and 98.5% had a smoking history. Sixty percent received nivolumab, 21.5% received atezolizumab and 18.5% received pembrolizumab. The median cycle of ICI was 4 cycles. Radiological patterns of IP were UIP (11%), probable UIP (15%), indeterminate for UIP (51%), alternative (23%), respectively, with 23% having honeycomb lung and a median %FVC of 95%. The incidence of pneumonitis was 23.1% for all grade and 13.9% for ≥grade3. We could not identify any significant risk factors for ICI-induced pneumonitis in the multivariate logistic regression analysis. There was no difference in the incidence and severity of ICI-induced pneumonitis when comparing patients with and without honeycomb lung, or with FVC ≥80% and <80%.
Conclusions
There was no difference in the risk of ICI-induced pneumonitis according to specific findings, including the radiological pattern of comorbid IP, the presence of honeycomb lung, and pulmonary function tests. ICIs should be carefully administrated in NSCLC with any types of comorbid IP.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
S. Ikeda: Financial Interests, Personal, Advisory Board: AstraZeneca, Chugai, Ono, Daiichi Sankyo; Financial Interests, Personal, Invited Speaker: AstraZeneca, Chugai, Ono, Bristol Myers Squibb, Taiho, Eli Lilly, Pfizer, Boehringer Ingelheim, Takeda; Financial Interests, Personal, Research Grant: AstraZeneca, Chugai. J. Sakakibara-Konishi: Financial Interests, Personal, Research Grant: eli Lilly. K. Yokoo: Financial Interests, Personal, Invited Speaker: AstraZeneca, Chugai, Eli Lilly, Kyowa Kirin, MerckBiopharma, Novartis, Terumo, Takeda, Nippon Kayaku, Bristol Myers Squibb. T. Iwasawa: Financial Interests, Personal, Advisory Board: CANON Medical Systems, Ziosoft I; Financial Interests, Personal, Invited Speaker: Boehringer Ingelheim. T. Misumi: Financial Interests, Personal, Invited Speaker: Miyarisan. T. Ogura: Financial Interests, Personal, Invited Speaker: Japanese Boehringer Ingelheim, Shionogi; Financial Interests, Personal, Advisory Board: BMS, Japanese Boehringer Ingelheim, Taiho, Shionogi. All other authors have declared no conflicts of interest.
Resources from the same session
62P - Combination of chemotherapy with endocrinal therapy as upfront treatment of metastatic breast cancer in hormone receptor- positive, HER2 -negative disease: A phase II randomised clinical trial
Presenter: Mariam Saleh
Session: Poster Display
Resources:
Abstract
63P - Efficacy and safety of eribulin plus carboplatin combination for HER2-negative metastatic breast cancer
Presenter: Mengqian Ni
Session: Poster Display
Resources:
Abstract
64P - Unmet needs following metastatic breast cancer in a middle-income Asian country
Presenter: Nirmala Bhoo-Pathy
Session: Poster Display
Resources:
Abstract
66P - Utidelone-based therapy in metastatic solid tumors after failure of standard therapies: A prospective, multicenter, single-arm trial
Presenter: Jianjun Zhang
Session: Poster Display
Resources:
Abstract
67P - Efficacy and safety of trastuzumab biosimilar in HER2+ve metastatic breast cancer: A multicenter phase III study
Presenter: krishna Mohan
Session: Poster Display
Resources:
Abstract
68P - Neratinib in combination with fulvestrant and or palbociclib can overcome endocrine resistance in HER2-low/ ER+ breast cancer
Presenter: Maryam Arshad
Session: Poster Display
Resources:
Abstract
69P - A multicenter, retrospective, real-world study of inetetamab combined with pyrotinib and vinorelbine as treatment for HER2-positive metastatic breast cancer
Presenter: Nan Jin
Session: Poster Display
Resources:
Abstract
70P - Overall survival of eribulin, trastuzumab, and pertuzumab as first-line therapy for patients with HER2-positive metastatic breast cancer: A phase II, single-arm clinical trial
Presenter: Kenichi Inoue
Session: Poster Display
Resources:
Abstract
71P - Efficacy and safety of disitamab vedotin after trastuzumab for HER2 -positive breast cancer: A real-world data of retrospective study
Presenter: Chao Li
Session: Poster Display
Resources:
Abstract
72P - Real-world data on the efficacy of T-DM1 biosimilar for the treatment of HER2-positive metastatic breast cancer patients: Outcomes from a single center retrospective study in India
Presenter: Kaushal Patel
Session: Poster Display
Resources:
Abstract